Loss of 14-3-3σ has been observed in multiple tumor types, however, the mechanisms by which 14-3-3σ loss leads to tumor progression are not understood. The experiments in this report demonstrate that loss of 14-3-3σ leads to a decrease in the expression of epithelial markers and an increase in the expression of mesenchymal markers, which is indicative of an induction of the epithelial to mesenchymal transition (EMT). The EMT was accompanied by an increase in migration and invasion in the 14-3-3σ -/- cells. 14-3-3σ-/- cells show increased stabilization of c-Jun resulting in an increase in the expression of the EMT transcription factor, Slug. 14-3-3σ induces the ubiquitination and degradation of c-Jun in an FBW7 dependent manner. c-Jun ubiquitination is dependent on the presence of an intact nuclear export pathway as c-Jun is stabilized and localized to the nucleus in the presence of a nuclear export inhibitor. Further, the absence of 14-3-3σ leads to the nuclear accumulation and stabilization of c-Jun suggesting that 14-3-3σ regulates the sub-cellular localization of c-Jun. Our results have identified a novel mechanism by which 14-3-3σ maintains the epithelial phenotype by inhibiting EMT and that this property of 14-3-3σ might contribute to its function as a tumor suppressor gene.
Interleukin 10 (IL10) is known for its anti-inflammatory function and is produced by different types of immune cells. However, the mechanism by which IL10 limits inflammation is not very clear. In this paper the authors have identified mTOR-Akt mediated metabolic reprograming as one of the pathways targeted by IL10 in macrophages. IL10 signaling through STAT3 leads to induction of DDIT4, which is an mTOR inhibitor. Loss of IL10 leads to mTOR activation, which further leads to increase in glucose uptake, glycolysis and concomitant decrease in mitochondrial oxidative phosphorylation, with a consequent decrease in rate of mitophagy, accumulation of dysfunctional mitochondria and increased levels mitochondrial reactive oxygen species (ROS). Dysregulation of the metabolic program in IL10 deficient macrophages led to aberrant activation of the inflammasome and capsase-1 mediated increased IL1b production. The authors also demonstrate that human monocyte derived macrophages from patients with a mutation in IL10 receptor produced increased amounts of IL1b upon lipopolysaccharide (LPS) stimulation and showed increased mTOR activity due to suppression of DDIT4, corroborating that the pathways regulated by IL-10 are similar in humans and mice. These well controlled and elegantly designed experiments demonstrate that IL10 limits inflammation in response to external stimuli by controlling mTOR mediated metabolic reprograming in macrophages, and that failure of this pathway leads to inflammasome activation and IL1b production. This study thus identifies targets of potential therapeutic intervention in inflammatory disease.